Evidence indicates that patients with peripheral arterial disease benefit from dual pathway antithrombotic therapy or prophylaxis (such as low-dose rivaroxaban combined with aspirin) to reduce both arterial and venous thrombotic events.
The claim states that peripheral arterial disease requires prophylaxis against venous thrombosis (or dual pathway/antithrombotic prophylaxis addressing both). Papers 0, 1, and 7 all provide support for using anticoagulant regimens (such as low-dose rivaroxaban plus aspirin) in peripheral arterial disease populations to manage thrombotic risks. No papers refute this claim.